| II-05 Mahmoud Ali Evaluation of the robustness of methods for model-based bioequivalence analysis for biosimilars: Clenoliximab as a case study Wednesday 15:35-17:00 |
| II-05 Mahmoud Ali Evaluation of the robustness of methods for model-based bioequivalence analysis for biosimilars: Clenoliximab as a case study Wednesday 15:35-17:00 |